{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:20:32Z","timestamp":1774383632700,"version":"3.50.1"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_rir-2025-0010_s_101\">\n                  <jats:title>Background and Objectives<\/jats:title>\n                  <jats:p>Biologic therapy has been used for Beh\u00e7et\u2019s Syndrome after first-line immunomodulation, but in the absence of high-quality evidence or predictive biomarkers. BIO-BEH\u00c7ET\u2019S was a randomized controlled clinical trial to compare the two most widely used biologics for Beh\u00e7et\u2019s Syndrome at that time, infliximab versus interferon-\u03b12a, and identify potential biomarkers for response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_rir-2025-0010_s_102\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 79 patients with active Beh\u00e7et\u2019s Syndrome were randomized to either infliximab (REMICADE) or interferon-\u03b12a (ROFERON) according to the UK national treatment pathway, and follow-up with symptom-directed examination undertaken at Weeks 12 and 24. The head-to-head trial included an exploratory analysis on the potential role of single nucleotide polymorphisms (SNPs) and urinary metabolomic to act as biomarkers for drug response. Genotypic analysis was performed to determine whether four SNPs in <jats:italic>IFNL3<\/jats:italic> and <jats:italic>IFNL4<\/jats:italic> \u2013 selected based on known effects \u2013 impacted primary and secondary outcomes. For metabolomic analyses, urine samples were analyzed by nuclear magnetic resonance spectroscopy and principal component analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_rir-2025-0010_s_103\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Genetic data suggested potential association between outcomes and carriage of rs4803221 or rs7248668 variants in the <jats:italic>IFNL3<\/jats:italic> (IL-28B) gene locus for interferon-\u03b12a patients; however, with the relatively small sample, statistical significance was lost when corrected for multiple testing. Metabolomic analysis identified potential markers of metabolic response to infliximab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_rir-2025-0010_s_104\">\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BIO-BEH\u00c7ET\u2019S suggests there is potential for a novel metabolomic biomarker that can identify response to infliximab in patients with Beh\u00e7et\u2019s Syndrome. Further work will characterize the appropriate metabolite (s) from existing samples to inform future prospective trials to study this in more detail clinically.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/rir-2025-0010","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:55:18Z","timestamp":1751392518000},"page":"70-79","source":"Crossref","is-referenced-by-count":1,"title":["Predicting response to infliximab and interferon-\u03b1 in Beh\u00e7et\u2019s syndrome: An exploratory analysis from the BIO-BEH\u00c7ET\u2019S randomized controlled trial"],"prefix":"10.1515","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-6211","authenticated-orcid":false,"given":"Robert J.","family":"Moots","sequence":"first","affiliation":[{"name":"Faculty of Health, Social Care and Medicine, Edge Hill University , Ormskirk , UK"},{"name":"Department of Academic Rheumatology, Liverpool University Hospitals NHS Foundation Trust, Aintree University Hospital, Longmoor Lane , Liverpool , L9 7AL , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farida","family":"Fortune","sequence":"additional","affiliation":[{"name":"Queen Mary University of London, UK; Barts Health NHS Trust, The London Hospital , London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Jackson","sequence":"additional","affiliation":[{"name":"Liverpool Clinical Trials Centre, University of Liverpool , Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Thornburn","sequence":"additional","affiliation":[{"name":"Beh\u00e7et\u2019s UK , Kemp House, 152\u2013160 City Road , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann W.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust , Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Carr","sequence":"additional","affiliation":[{"name":"Institute of Systems, Molecular and Integrated Biology, University of Liverpool , Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip I.","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Ageing, University of Birmingham , Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Ageing, University of Birmingham , Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Ageing, University of Birmingham , Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deva","family":"Situnayake","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sandwell and West Birmingham Hospitals , Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025070117550979888_j_rir-2025-0010_ref_001","doi-asserted-by":"crossref","unstructured":"Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77:808\u2013818.","DOI":"10.1136\/annrheumdis-2018-213225"},{"key":"2025070117550979888_j_rir-2025-0010_ref_002","doi-asserted-by":"crossref","unstructured":"van der Houwen T and van Laar J. Beh\u04abet\u2019s Disease, and the Role of TNF-\u03b1 and TNF-\u03b1 Blockers. Int J Mol Sci. 2020;21:3072.","DOI":"10.3390\/ijms21093072"},{"key":"2025070117550979888_j_rir-2025-0010_ref_003","doi-asserted-by":"crossref","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, et al. The use of interferon alpha in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum. 2004;33:320\u2013335.","DOI":"10.1016\/j.semarthrit.2003.09.010"},{"key":"2025070117550979888_j_rir-2025-0010_ref_004","doi-asserted-by":"crossref","unstructured":"Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease. Arch Ophthalmol. 2012;130:592\u2013598.","DOI":"10.1001\/archophthalmol.2011.2698"},{"key":"2025070117550979888_j_rir-2025-0010_ref_005","doi-asserted-by":"crossref","unstructured":"Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa. Arch Dermatol. 1998;134:1010\u20131016.","DOI":"10.1001\/archderm.134.8.1010"},{"key":"2025070117550979888_j_rir-2025-0010_ref_006","doi-asserted-by":"crossref","unstructured":"Takeuchi M, Ombrello MJ, Kirino Y, et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Beh\u00e7et\u2019s disease in HLA-B*51 carriers. Ann Rheum Dis. 2016;75:2208\u20132211.","DOI":"10.1136\/annrheumdis-2015-209059"},{"key":"2025070117550979888_j_rir-2025-0010_ref_007","doi-asserted-by":"crossref","unstructured":"Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Beh\u00e7et\u2019s disease: A comprehensive review. J Autoimmun. 2015;64:137\u2013148.","DOI":"10.1016\/j.jaut.2015.08.013"},{"key":"2025070117550979888_j_rir-2025-0010_ref_008","doi-asserted-by":"crossref","unstructured":"Takeuchi M, Mizuki N, Meguro A, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Beh\u00e7et\u2019s disease susceptibility. Nat Genet. 2017;49:438\u2013443.","DOI":"10.1038\/ng.3786"},{"key":"2025070117550979888_j_rir-2025-0010_ref_009","doi-asserted-by":"crossref","unstructured":"Moots RJ, Fortune F, Jackson R, et al. Infliximab versus interferon-alpha in the treatment of Beh\u00e7et\u2019s Syndrome: Clinical data from the BIO-BEH\u00c7ET\u2019S randomised controlled trial. Rheumatology (Oxford). 2025;64:2882-2891.","DOI":"10.1093\/rheumatology\/keae585"},{"key":"2025070117550979888_j_rir-2025-0010_ref_010","doi-asserted-by":"crossref","unstructured":"Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399\u2013401.","DOI":"10.1038\/nature08309"},{"key":"2025070117550979888_j_rir-2025-0010_ref_011","doi-asserted-by":"crossref","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100\u20131104.","DOI":"10.1038\/ng.447"},{"key":"2025070117550979888_j_rir-2025-0010_ref_012","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105\u20131109.","DOI":"10.1038\/ng.449"},{"key":"2025070117550979888_j_rir-2025-0010_ref_013","doi-asserted-by":"crossref","unstructured":"Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120\u2013129.","DOI":"10.4016\/19518.01"},{"key":"2025070117550979888_j_rir-2025-0010_ref_014","doi-asserted-by":"crossref","unstructured":"Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology. 2011;53:336\u2013345.","DOI":"10.1002\/hep.24052"},{"key":"2025070117550979888_j_rir-2025-0010_ref_015","doi-asserted-by":"crossref","unstructured":"Smith KR, Suppiah V, O\u2019Connor K, et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 2011;3:57.","DOI":"10.1186\/gm273"},{"key":"2025070117550979888_j_rir-2025-0010_ref_016","doi-asserted-by":"crossref","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164\u2013171.","DOI":"10.1038\/ng.2521"},{"key":"2025070117550979888_j_rir-2025-0010_ref_017","doi-asserted-by":"crossref","unstructured":"Lai M, Afdhal NH. Clinical utility of interleukin-28B testing in patients with genotype 1. Hepatology. 2012;56:367\u2013372.","DOI":"10.1002\/hep.25793"},{"key":"2025070117550979888_j_rir-2025-0010_ref_018","unstructured":"Hatemi G, Seyahi E, Fresko I, et al. Behcet\u2019s syndrome: a critical digest of the 2012\u20132013 literature. Clin Exp Rheumatol. 2013;31:108\u2013117."},{"key":"2025070117550979888_j_rir-2025-0010_ref_019","unstructured":"Beh\u00e7et\u2019s Syndrome Centres of Excellent. Available at: https:\/\/behcetsuk.org\/national-behcets-centres-of-excellence\/. Accessed November 06, 2025."},{"key":"2025070117550979888_j_rir-2025-0010_ref_020","doi-asserted-by":"crossref","unstructured":"Ludwig C. MetaboLabPy-An Open-Source Software Package for Metabolomics NMR Data Processing and Metabolic Tracer Data Analysis. Metabolites. 2025;15:48.","DOI":"10.3390\/metabo15010048"},{"key":"2025070117550979888_j_rir-2025-0010_ref_021","doi-asserted-by":"crossref","unstructured":"Kapoor SR, Filer A, Fitzpatrick MA, et al. Metabolic profiling predicts response to anti-tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:1448\u20131456.","DOI":"10.1002\/art.37921"},{"key":"2025070117550979888_j_rir-2025-0010_ref_022","doi-asserted-by":"crossref","unstructured":"Ahn JK, Kim J, Hwang J, et al. Urinary Metabolomic Profiling to Identify Potential Biomarkers for the Diagnosis of Behcet\u2019s Disease by Gas Chromatography\/Time-of-Flight-Mass Spectrometry. Int J Mol Sci. 2017;18:2309.","DOI":"10.3390\/ijms18112309"},{"key":"2025070117550979888_j_rir-2025-0010_ref_023","doi-asserted-by":"crossref","unstructured":"Zheng W, Wu X, Goudarzi M, et al. Metabolomic alterations associated with Beh\u00e7et\u2019s disease. Arthritis Res Ther. 2018;20:214.","DOI":"10.1186\/s13075-018-1712-y"},{"key":"2025070117550979888_j_rir-2025-0010_ref_024","doi-asserted-by":"crossref","unstructured":"Ahn JK, Kim J, Hwang J, et al. Potential metabolomic biomarkers for reliable diagnosis of Behcet\u2019s disease using gas chromatography\/ time-of-flight-mass spectrometry. Joint Bone Spine. 2018;85:337\u2013343.","DOI":"10.1016\/j.jbspin.2017.05.019"},{"key":"2025070117550979888_j_rir-2025-0010_ref_025","doi-asserted-by":"crossref","unstructured":"Ahn JK, Kim S, Kim J, et al. A Comparative Metabolomic Evaluation of Behcet\u2019s Disease with Arthritis and Seronegative Arthritis Using Synovial Fluid. PLoS One. 2015;10:e0135856.","DOI":"10.1371\/journal.pone.0135856"},{"key":"2025070117550979888_j_rir-2025-0010_ref_026","doi-asserted-by":"crossref","unstructured":"Yal\u00e7indag N, K\u00f6se HC. Comparison of the Treatment Results for Beh\u00e7et Uveitis in Patients Treated with Infliximab and Interferon. Ocul Immunol Inflamm. 2020;28:305\u2013314.","DOI":"10.1080\/09273948.2019.1606256"}],"container-title":["Rheumatology and Immunology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/rir-2025-0010\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/rir-2025-0010\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:55:31Z","timestamp":1751392531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/rir-2025-0010\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7,1]]}},"alternative-id":["10.1515\/rir-2025-0010"],"URL":"https:\/\/doi.org\/10.1515\/rir-2025-0010","relation":{},"ISSN":["2719-4523"],"issn-type":[{"value":"2719-4523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}